57473-33-3 Usage
Uses
Used in Pharmaceutical Industry:
7-chloroimidazo[1,2-a]pyrimidin-5(1H)-one is used as a potential drug candidate for the development of new medications to treat various medical conditions. Its unique chemical structure and properties make it a promising molecule for further research and development.
The specific applications and reasons for using 7-chloroimidazo[1,2-a]pyrimidin-5(1H)-one in the pharmaceutical industry are not provided in the materials. However, given its status as a heterocyclic organic compound and a derivative of imidazo[1,2-a]pyrimidine, it is likely that 7-chloroiMidazo[1,2-a]pyriMidin-5(1H)-one could be used in the development of drugs targeting specific biological pathways or receptors, potentially leading to the treatment of various diseases and conditions.
Further research is needed to fully understand and explore the potential uses and applications of 7-chloroimidazo[1,2-a]pyrimidin-5(1H)-one, as well as to determine its safety, efficacy, and optimal dosage for any potential medical applications.
Check Digit Verification of cas no
The CAS Registry Mumber 57473-33-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,7,4,7 and 3 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 57473-33:
(7*5)+(6*7)+(5*4)+(4*7)+(3*3)+(2*3)+(1*3)=143
143 % 10 = 3
So 57473-33-3 is a valid CAS Registry Number.
57473-33-3Relevant academic research and scientific papers
Synthesis and structure-activity relationships of imidazo[1,2-a]pyrimidin- 5(1H)-ones as a novel series of beta isoform selective phosphatidylinositol 3-kinase inhibitors
Lin, Hong,Erhard, Karl,Hardwicke, Mary Ann,Luengo, Juan I.,MacK, James F.,McSurdy-Freed, Jeanelle,Plant, Ramona,Raha, Kaushik,Rominger, Cynthia M.,Sanchez, Robert M.,Schaber, Michael D.,Schulz, Mark J.,Spengler, Michael D.,Tedesco, Rosanna,Xie, Ren,Zeng, Jin J.,Rivero, Ralph A.
scheme or table, p. 2230 - 2234 (2012/04/18)
A series of PI3K-beta selective inhibitors, imidazo[1,2-a]-pyrimidin-5(1H)- ones, has been rationally designed based on the docking model of the more potent R enantiomer of TGX-221, identified by a chiral separation, in a PI3K-beta homology model. Synthesis and SAR of this novel chemotype are described. Several compounds in the series demonstrated potent growth inhibition in a PTEN-deficient breast cancer cell line MDA-MB-468 under anchorage independent conditions.
